Pear Therapeutics, Inc.
Pear Therapeutics, Inc. (PEAR) Stock Competitors & Peer Comparison
See (PEAR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PEAR | $0.03 | +0.00% | 4.1M | -0.08 | -$0.36 | N/A |
| BTSGU | $186.42 | +1.17% | 36.2B | N/A | N/A | N/A |
| GEHC | $61.89 | -0.64% | 28.2B | 14.84 | $4.17 | +0.23% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| VEEV | $155.73 | -2.31% | 25.4B | 28.63 | $5.44 | N/A |
| BTSG | $56.50 | +1.80% | 11B | 73.38 | $0.77 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| TEM | $45.90 | -2.24% | 8B | -26.68 | -$1.72 | N/A |
| HQY | $82.18 | +2.14% | 6.9B | 33.41 | $2.46 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
PEAR vs BTSGU Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BTSGU has a market cap of 36.2B. Regarding current trading prices, PEAR is priced at $0.03, while BTSGU trades at $186.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BTSGU's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check BTSGU's competition here
PEAR vs GEHC Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, GEHC has a market cap of 28.2B. Regarding current trading prices, PEAR is priced at $0.03, while GEHC trades at $61.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas GEHC's P/E ratio is 14.84. In terms of profitability, PEAR's ROE is -0.39%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PEAR is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check GEHC's competition here
PEAR vs GEHCV Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, PEAR is priced at $0.03, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas GEHCV's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, PEAR is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check GEHCV's competition here
PEAR vs VEEV Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, VEEV has a market cap of 25.4B. Regarding current trading prices, PEAR is priced at $0.03, while VEEV trades at $155.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas VEEV's P/E ratio is 28.63. In terms of profitability, PEAR's ROE is -0.39%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, PEAR is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check VEEV's competition here
PEAR vs BTSG Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BTSG has a market cap of 11B. Regarding current trading prices, PEAR is priced at $0.03, while BTSG trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BTSG's P/E ratio is 73.38. In terms of profitability, PEAR's ROE is -0.39%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check BTSG's competition here
PEAR vs SGFY Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, PEAR is priced at $0.03, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SGFY's P/E ratio is 70.91. In terms of profitability, PEAR's ROE is -0.39%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, PEAR is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SGFY's competition here
PEAR vs TEM Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TEM has a market cap of 8B. Regarding current trading prices, PEAR is priced at $0.03, while TEM trades at $45.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TEM's P/E ratio is -26.68. In terms of profitability, PEAR's ROE is -0.39%, compared to TEM's ROE of -0.70%. Regarding short-term risk, PEAR is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check TEM's competition here
PEAR vs HQY Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HQY has a market cap of 6.9B. Regarding current trading prices, PEAR is priced at $0.03, while HQY trades at $82.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HQY's P/E ratio is 33.41. In terms of profitability, PEAR's ROE is -0.39%, compared to HQY's ROE of +0.10%. Regarding short-term risk, PEAR is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check HQY's competition here
PEAR vs RCM Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, PEAR is priced at $0.03, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas RCM's P/E ratio is -102.21. In terms of profitability, PEAR's ROE is -0.39%, compared to RCM's ROE of +0.00%. Regarding short-term risk, PEAR is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check RCM's competition here
PEAR vs DOCS Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, DOCS has a market cap of 4.4B. Regarding current trading prices, PEAR is priced at $0.03, while DOCS trades at $23.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas DOCS's P/E ratio is 19.66. In terms of profitability, PEAR's ROE is -0.39%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, PEAR is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check DOCS's competition here
PEAR vs HNGE Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HNGE has a market cap of 4.2B. Regarding current trading prices, PEAR is priced at $0.03, while HNGE trades at $54.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HNGE's P/E ratio is -6.07. In terms of profitability, PEAR's ROE is -0.39%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, PEAR is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check HNGE's competition here
PEAR vs ONEM Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, PEAR is priced at $0.03, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ONEM's P/E ratio is -7.77. In terms of profitability, PEAR's ROE is -0.39%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, PEAR is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check ONEM's competition here
PEAR vs PRVA Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PRVA has a market cap of 2.9B. Regarding current trading prices, PEAR is priced at $0.03, while PRVA trades at $22.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PRVA's P/E ratio is 133.12. In terms of profitability, PEAR's ROE is -0.39%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, PEAR is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check PRVA's competition here
PEAR vs HTFL Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HTFL has a market cap of 2.7B. Regarding current trading prices, PEAR is priced at $0.03, while HTFL trades at $31.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HTFL's P/E ratio is -9.84. In terms of profitability, PEAR's ROE is -0.39%, compared to HTFL's ROE of +0.38%. Regarding short-term risk, PEAR is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check HTFL's competition here
PEAR vs TXG Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TXG has a market cap of 2.7B. Regarding current trading prices, PEAR is priced at $0.03, while TXG trades at $21.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TXG's P/E ratio is -123.94. In terms of profitability, PEAR's ROE is -0.39%, compared to TXG's ROE of -0.03%. Regarding short-term risk, PEAR is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check TXG's competition here
PEAR vs PINC Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, PEAR is priced at $0.03, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PINC's P/E ratio is 166.24. In terms of profitability, PEAR's ROE is -0.39%, compared to PINC's ROE of -0.02%. Regarding short-term risk, PEAR is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check PINC's competition here
PEAR vs OMCL Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, OMCL has a market cap of 2B. Regarding current trading prices, PEAR is priced at $0.03, while OMCL trades at $43.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas OMCL's P/E ratio is 98.11. In terms of profitability, PEAR's ROE is -0.39%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, PEAR is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check OMCL's competition here
PEAR vs PGNY Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PGNY has a market cap of 1.8B. Regarding current trading prices, PEAR is priced at $0.03, while PGNY trades at $23.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PGNY's P/E ratio is 30.53. In terms of profitability, PEAR's ROE is -0.39%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, PEAR is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check PGNY's competition here
PEAR vs NXGN Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, PEAR is priced at $0.03, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas NXGN's P/E ratio is -266.00. In terms of profitability, PEAR's ROE is -0.39%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, PEAR is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check NXGN's competition here
PEAR vs AGTI Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, PEAR is priced at $0.03, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AGTI's P/E ratio is -71.79. In terms of profitability, PEAR's ROE is -0.39%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, PEAR is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check AGTI's competition here
PEAR vs TDOC Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, PEAR is priced at $0.03, while TDOC trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TDOC's P/E ratio is -0.23. In terms of profitability, PEAR's ROE is -0.39%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, PEAR is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check TDOC's competition here
PEAR vs WGS Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, WGS has a market cap of 1.2B. Regarding current trading prices, PEAR is priced at $0.03, while WGS trades at $38.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas WGS's P/E ratio is -14.64. In terms of profitability, PEAR's ROE is -0.39%, compared to WGS's ROE of -0.28%. Regarding short-term risk, PEAR is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check WGS's competition here
PEAR vs OMDA Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, OMDA has a market cap of 953.6M. Regarding current trading prices, PEAR is priced at $0.03, while OMDA trades at $16.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas OMDA's P/E ratio is -69.74. In terms of profitability, PEAR's ROE is -0.39%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, PEAR is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check OMDA's competition here
PEAR vs SDGR Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SDGR has a market cap of 952.7M. Regarding current trading prices, PEAR is priced at $0.03, while SDGR trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SDGR's P/E ratio is -9.11. In terms of profitability, PEAR's ROE is -0.39%, compared to SDGR's ROE of -0.31%. Regarding short-term risk, PEAR is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SDGR's competition here
PEAR vs GDRX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, GDRX has a market cap of 904.7M. Regarding current trading prices, PEAR is priced at $0.03, while GDRX trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas GDRX's P/E ratio is 43.50. In terms of profitability, PEAR's ROE is -0.39%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, PEAR is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check GDRX's competition here
PEAR vs CCLDO Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CCLDO has a market cap of 859.2M. Regarding current trading prices, PEAR is priced at $0.03, while CCLDO trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CCLDO's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CCLDO's competition here
PEAR vs NUTX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, NUTX has a market cap of 785.4M. Regarding current trading prices, PEAR is priced at $0.03, while NUTX trades at $131.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas NUTX's P/E ratio is 9.65. In terms of profitability, PEAR's ROE is -0.39%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, PEAR is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check NUTX's competition here
PEAR vs CERT Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CERT has a market cap of 745.9M. Regarding current trading prices, PEAR is priced at $0.03, while CERT trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CERT's P/E ratio is -47.95. In terms of profitability, PEAR's ROE is -0.39%, compared to CERT's ROE of -0.01%. Regarding short-term risk, PEAR is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CERT's competition here
PEAR vs HSTM Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HSTM has a market cap of 668.7M. Regarding current trading prices, PEAR is priced at $0.03, while HSTM trades at $22.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HSTM's P/E ratio is 34.16. In terms of profitability, PEAR's ROE is -0.39%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, PEAR is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check HSTM's competition here
PEAR vs MPLN-WT Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, PEAR is priced at $0.03, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, PEAR is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PEAR.Check MPLN-WT's competition here
PEAR vs ACCD Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, PEAR is priced at $0.03, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ACCD's P/E ratio is -3.08. In terms of profitability, PEAR's ROE is -0.39%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, PEAR is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check ACCD's competition here
PEAR vs PHR Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PHR has a market cap of 558.7M. Regarding current trading prices, PEAR is priced at $0.03, while PHR trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PHR's P/E ratio is 229.88. In terms of profitability, PEAR's ROE is -0.39%, compared to PHR's ROE of +0.01%. Regarding short-term risk, PEAR is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check PHR's competition here
PEAR vs SHCR Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, PEAR is priced at $0.03, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SHCR's P/E ratio is -3.76. In terms of profitability, PEAR's ROE is -0.39%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, PEAR is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SHCR's competition here
PEAR vs CTEV Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CTEV has a market cap of 472.4M. Regarding current trading prices, PEAR is priced at $0.03, while CTEV trades at $27.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CTEV's P/E ratio is -1.60. In terms of profitability, PEAR's ROE is -0.39%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, PEAR is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CTEV's competition here
PEAR vs EVH Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, EVH has a market cap of 464.5M. Regarding current trading prices, PEAR is priced at $0.03, while EVH trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas EVH's P/E ratio is -0.88. In terms of profitability, PEAR's ROE is -0.39%, compared to EVH's ROE of -0.78%. Regarding short-term risk, PEAR is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check EVH's competition here
PEAR vs NRC Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, NRC has a market cap of 420.8M. Regarding current trading prices, PEAR is priced at $0.03, while NRC trades at $18.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas NRC's P/E ratio is 47.87. In terms of profitability, PEAR's ROE is -0.39%, compared to NRC's ROE of +0.57%. Regarding short-term risk, PEAR is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check NRC's competition here
PEAR vs SLGCW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, PEAR is priced at $0.03, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, PEAR's ROE is -0.39%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, PEAR is more volatile compared to SLGCW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SLGCW's competition here
PEAR vs SLGC Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, PEAR is priced at $0.03, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SLGC's P/E ratio is -3.04. In terms of profitability, PEAR's ROE is -0.39%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, PEAR is more volatile compared to SLGC. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SLGC's competition here
PEAR vs TBRG Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TBRG has a market cap of 387.6M. Regarding current trading prices, PEAR is priced at $0.03, while TBRG trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TBRG's P/E ratio is 89.10. In terms of profitability, PEAR's ROE is -0.39%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, PEAR is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check TBRG's competition here
PEAR vs SY Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SY has a market cap of 381.6M. Regarding current trading prices, PEAR is priced at $0.03, while SY trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SY's P/E ratio is -8.29. In terms of profitability, PEAR's ROE is -0.39%, compared to SY's ROE of -0.14%. Regarding short-term risk, PEAR is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SY's competition here
PEAR vs MPLN Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, PEAR is priced at $0.03, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MPLN's P/E ratio is -0.23. In terms of profitability, PEAR's ROE is -0.39%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, PEAR is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check MPLN's competition here
PEAR vs SOPH Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SOPH has a market cap of 323.2M. Regarding current trading prices, PEAR is priced at $0.03, while SOPH trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SOPH's P/E ratio is -3.82. In terms of profitability, PEAR's ROE is -0.39%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, PEAR is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SOPH's competition here
PEAR vs TRHC Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, PEAR is priced at $0.03, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas TRHC's P/E ratio is -4.27. In terms of profitability, PEAR's ROE is -0.39%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, PEAR is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check TRHC's competition here
PEAR vs CARL Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CARL has a market cap of 278.1M. Regarding current trading prices, PEAR is priced at $0.03, while CARL trades at $10.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CARL's P/E ratio is -10.55. In terms of profitability, PEAR's ROE is -0.39%, compared to CARL's ROE of -0.62%. Regarding short-term risk, PEAR is more volatile compared to CARL. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CARL's competition here
PEAR vs SLP Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SLP has a market cap of 274.2M. Regarding current trading prices, PEAR is priced at $0.03, while SLP trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SLP's P/E ratio is -4.35. In terms of profitability, PEAR's ROE is -0.39%, compared to SLP's ROE of -0.49%. Regarding short-term risk, PEAR is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SLP's competition here
PEAR vs SMFR Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, PEAR is priced at $0.03, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SMFR's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, PEAR is more volatile compared to SMFR. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SMFR's competition here
PEAR vs SPOK Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SPOK has a market cap of 228.5M. Regarding current trading prices, PEAR is priced at $0.03, while SPOK trades at $10.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SPOK's P/E ratio is 18.54. In terms of profitability, PEAR's ROE is -0.39%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, PEAR is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SPOK's competition here
PEAR vs CPSI Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, PEAR is priced at $0.03, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CPSI's P/E ratio is -183.80. In terms of profitability, PEAR's ROE is -0.39%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, PEAR is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CPSI's competition here
PEAR vs AMWL Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AMWL has a market cap of 129.7M. Regarding current trading prices, PEAR is priced at $0.03, while AMWL trades at $7.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AMWL's P/E ratio is -1.43. In terms of profitability, PEAR's ROE is -0.39%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, PEAR is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check AMWL's competition here
PEAR vs AUGX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, PEAR is priced at $0.03, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AUGX's P/E ratio is -4.99. In terms of profitability, PEAR's ROE is -0.39%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, PEAR is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check AUGX's competition here
PEAR vs HCAT Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HCAT has a market cap of 99M. Regarding current trading prices, PEAR is priced at $0.03, while HCAT trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HCAT's P/E ratio is -0.36. In terms of profitability, PEAR's ROE is -0.39%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, PEAR is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check HCAT's competition here
PEAR vs DH Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, DH has a market cap of 93.5M. Regarding current trading prices, PEAR is priced at $0.03, while DH trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas DH's P/E ratio is -0.53. In terms of profitability, PEAR's ROE is -0.39%, compared to DH's ROE of -0.67%. Regarding short-term risk, PEAR is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check DH's competition here
PEAR vs OPRX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, OPRX has a market cap of 92.2M. Regarding current trading prices, PEAR is priced at $0.03, while OPRX trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas OPRX's P/E ratio is 18.20. In terms of profitability, PEAR's ROE is -0.39%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, PEAR is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check OPRX's competition here
PEAR vs CCLD Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CCLD has a market cap of 90.1M. Regarding current trading prices, PEAR is priced at $0.03, while CCLD trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CCLD's P/E ratio is 16.31. In terms of profitability, PEAR's ROE is -0.39%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CCLD's competition here
PEAR vs FORA Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, FORA has a market cap of 67.5M. Regarding current trading prices, PEAR is priced at $0.03, while FORA trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas FORA's P/E ratio is -24.00. In terms of profitability, PEAR's ROE is -0.39%, compared to FORA's ROE of -0.09%. Regarding short-term risk, PEAR is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check FORA's competition here
PEAR vs CCLDP Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, PEAR is priced at $0.03, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CCLDP's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, PEAR is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CCLDP's competition here
PEAR vs BEAT Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BEAT has a market cap of 36M. Regarding current trading prices, PEAR is priced at $0.03, while BEAT trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BEAT's P/E ratio is -1.69. In terms of profitability, PEAR's ROE is -0.39%, compared to BEAT's ROE of -5.71%. Regarding short-term risk, PEAR is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check BEAT's competition here
PEAR vs SNCE Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, PEAR is priced at $0.03, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SNCE's P/E ratio is -0.27. In terms of profitability, PEAR's ROE is -0.39%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, PEAR is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SNCE's competition here
PEAR vs AKLI Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, PEAR is priced at $0.03, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas AKLI's P/E ratio is -0.71. In terms of profitability, PEAR's ROE is -0.39%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, PEAR is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check AKLI's competition here
PEAR vs SHLT Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, PEAR is priced at $0.03, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SHLT's P/E ratio is -3.87. In terms of profitability, PEAR's ROE is -0.39%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, PEAR is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SHLT's competition here
PEAR vs SHCRW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, PEAR is priced at $0.03, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, PEAR is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SHCRW's competition here
PEAR vs ONMD Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ONMD has a market cap of 30.5M. Regarding current trading prices, PEAR is priced at $0.03, while ONMD trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ONMD's P/E ratio is -15.52. In terms of profitability, PEAR's ROE is -0.39%, compared to ONMD's ROE of +0.41%. Regarding short-term risk, PEAR is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check ONMD's competition here
PEAR vs EUDA Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, EUDA has a market cap of 26.9M. Regarding current trading prices, PEAR is priced at $0.03, while EUDA trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas EUDA's P/E ratio is -9.72. In terms of profitability, PEAR's ROE is -0.39%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, PEAR is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check EUDA's competition here
PEAR vs STRM Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, PEAR is priced at $0.03, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas STRM's P/E ratio is -2.40. In terms of profitability, PEAR's ROE is -0.39%, compared to STRM's ROE of -0.32%. Regarding short-term risk, PEAR is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check STRM's competition here
PEAR vs RNLX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, PEAR is priced at $0.03, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas RNLX's P/E ratio is -0.33. In terms of profitability, PEAR's ROE is -0.39%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, PEAR is more volatile compared to RNLX. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check RNLX's competition here
PEAR vs LIFW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, PEAR is priced at $0.03, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas LIFW's P/E ratio is -0.02. In terms of profitability, PEAR's ROE is -0.39%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, PEAR is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check LIFW's competition here
PEAR vs BBLN Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, PEAR is priced at $0.03, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BBLN's P/E ratio is -0.04. In terms of profitability, PEAR's ROE is -0.39%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, PEAR is more volatile compared to BBLN. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check BBLN's competition here
PEAR vs ETAO Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, PEAR is priced at $0.03, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ETAO's P/E ratio is -0.01. In terms of profitability, PEAR's ROE is -0.39%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, PEAR is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for PEAR.Check ETAO's competition here
PEAR vs HLTH Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, PEAR is priced at $0.03, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HLTH's P/E ratio is -0.02. In terms of profitability, PEAR's ROE is -0.39%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, PEAR is more volatile compared to HLTH. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check HLTH's competition here
PEAR vs BFRG Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BFRG has a market cap of 6.7M. Regarding current trading prices, PEAR is priced at $0.03, while BFRG trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BFRG's P/E ratio is -1.00. In terms of profitability, PEAR's ROE is -0.39%, compared to BFRG's ROE of -2.73%. Regarding short-term risk, PEAR is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check BFRG's competition here
PEAR vs SCNX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, SCNX has a market cap of 6.3M. Regarding current trading prices, PEAR is priced at $0.03, while SCNX trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas SCNX's P/E ratio is -0.15. In terms of profitability, PEAR's ROE is -0.39%, compared to SCNX's ROE of -2.36%. Regarding short-term risk, PEAR is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check SCNX's competition here
PEAR vs UPH-WT Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, PEAR is priced at $0.03, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, PEAR is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PEAR.Check UPH-WT's competition here
PEAR vs UPH Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, PEAR is priced at $0.03, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas UPH's P/E ratio is -0.07. In terms of profitability, PEAR's ROE is -0.39%, compared to UPH's ROE of -1.05%. Regarding short-term risk, PEAR is more volatile compared to UPH. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check UPH's competition here
PEAR vs ZCMD Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ZCMD has a market cap of 4.8M. Regarding current trading prices, PEAR is priced at $0.03, while ZCMD trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ZCMD's P/E ratio is -0.81. In terms of profitability, PEAR's ROE is -0.39%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, PEAR is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check ZCMD's competition here
PEAR vs PEARW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, PEAR is priced at $0.03, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas PEARW's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, PEAR is more volatile compared to PEARW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check PEARW's competition here
PEAR vs MGRX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MGRX has a market cap of 3.4M. Regarding current trading prices, PEAR is priced at $0.03, while MGRX trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MGRX's P/E ratio is -0.16. In terms of profitability, PEAR's ROE is -0.39%, compared to MGRX's ROE of -1.17%. Regarding short-term risk, PEAR is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check MGRX's competition here
PEAR vs BFRGW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BFRGW has a market cap of 2.8M. Regarding current trading prices, PEAR is priced at $0.03, while BFRGW trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BFRGW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to BFRGW's ROE of -2.73%. Regarding short-term risk, PEAR is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check BFRGW's competition here
PEAR vs VSEE Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, VSEE has a market cap of 2.8M. Regarding current trading prices, PEAR is priced at $0.03, while VSEE trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas VSEE's P/E ratio is -0.24. In terms of profitability, PEAR's ROE is -0.39%, compared to VSEE's ROE of +6.29%. Regarding short-term risk, PEAR is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check VSEE's competition here
PEAR vs BEATW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, BEATW has a market cap of 2.6M. Regarding current trading prices, PEAR is priced at $0.03, while BEATW trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas BEATW's P/E ratio is -0.15. In terms of profitability, PEAR's ROE is -0.39%, compared to BEATW's ROE of -5.71%. Regarding short-term risk, PEAR is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check BEATW's competition here
PEAR vs HCTI Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, HCTI has a market cap of 2.5M. Regarding current trading prices, PEAR is priced at $0.03, while HCTI trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas HCTI's P/E ratio is -0.01. In terms of profitability, PEAR's ROE is -0.39%, compared to HCTI's ROE of -1.01%. Regarding short-term risk, PEAR is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check HCTI's competition here
PEAR vs OTRK Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, PEAR is priced at $0.03, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas OTRK's P/E ratio is -0.02. In terms of profitability, PEAR's ROE is -0.39%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, PEAR is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check OTRK's competition here
PEAR vs ACON Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ACON has a market cap of 1.7M. Regarding current trading prices, PEAR is priced at $0.03, while ACON trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ACON's P/E ratio is -0.24. In terms of profitability, PEAR's ROE is -0.39%, compared to ACON's ROE of -0.00%. Regarding short-term risk, PEAR is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check ACON's competition here
PEAR vs EUDAW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, EUDAW has a market cap of 1.7M. Regarding current trading prices, PEAR is priced at $0.03, while EUDAW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas EUDAW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, PEAR is more volatile compared to EUDAW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check EUDAW's competition here
PEAR vs CMAX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, PEAR is priced at $0.03, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CMAX's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, PEAR is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CMAX's competition here
PEAR vs LIFWZ Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, PEAR is priced at $0.03, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, PEAR is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check LIFWZ's competition here
PEAR vs VSEEW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, VSEEW has a market cap of 1M. Regarding current trading prices, PEAR is priced at $0.03, while VSEEW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas VSEEW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to VSEEW's ROE of +6.29%. Regarding short-term risk, PEAR is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for PEAR.Check VSEEW's competition here
PEAR vs MSPRZ Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, PEAR is priced at $0.03, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, PEAR is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for PEAR.Check MSPRZ's competition here
PEAR vs MSPR Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MSPR has a market cap of 451.1K. Regarding current trading prices, PEAR is priced at $0.03, while MSPR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MSPR's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, PEAR is more volatile compared to MSPR. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check MSPR's competition here
PEAR vs WORX Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, PEAR is priced at $0.03, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas WORX's P/E ratio is -0.12. In terms of profitability, PEAR's ROE is -0.39%, compared to WORX's ROE of -0.73%. Regarding short-term risk, PEAR is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for PEAR.Check WORX's competition here
PEAR vs WGSWW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, WGSWW has a market cap of 165K. Regarding current trading prices, PEAR is priced at $0.03, while WGSWW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas WGSWW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, PEAR is more volatile compared to WGSWW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check WGSWW's competition here
PEAR vs KERNW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, PEAR is priced at $0.03, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas KERNW's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, PEAR is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for PEAR.Check KERNW's competition here
PEAR vs KERN Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, PEAR is priced at $0.03, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas KERN's P/E ratio is -0.01. In terms of profitability, PEAR's ROE is -0.39%, compared to KERN's ROE of -0.17%. Regarding short-term risk, PEAR is more volatile compared to KERN. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check KERN's competition here
PEAR vs LIFWW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, PEAR is priced at $0.03, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas LIFWW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, PEAR is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check LIFWW's competition here
PEAR vs OTRKP Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, PEAR is priced at $0.03, while OTRKP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, PEAR's ROE is -0.39%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, PEAR is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for PEAR.Check OTRKP's competition here
PEAR vs CMAXW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, PEAR is priced at $0.03, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas CMAXW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, PEAR is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check CMAXW's competition here
PEAR vs ACONW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ACONW has a market cap of 18.2K. Regarding current trading prices, PEAR is priced at $0.03, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ACONW's P/E ratio is -0.01. In terms of profitability, PEAR's ROE is -0.39%, compared to ACONW's ROE of -0.00%. Regarding short-term risk, PEAR is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check ACONW's competition here
PEAR vs ICCT Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, PEAR is priced at $0.03, while ICCT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas ICCT's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, PEAR is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check ICCT's competition here
PEAR vs MSPRW Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, MSPRW has a market cap of 4.1K. Regarding current trading prices, PEAR is priced at $0.03, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas MSPRW's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, PEAR is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check MSPRW's competition here
PEAR vs FOXO Comparison May 2026
PEAR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEAR stands at 4.1M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, PEAR is priced at $0.03, while FOXO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEAR currently has a P/E ratio of -0.08, whereas FOXO's P/E ratio is N/A. In terms of profitability, PEAR's ROE is -0.39%, compared to FOXO's ROE of -0.91%. Regarding short-term risk, PEAR is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for PEAR.Check FOXO's competition here